Auauniversity

AUA2025: Sexual Medicine Society of North America Meeting Cohost: Landon Trost, MD Outline: Segment #1: What is the Sexual Medicine Society of North America and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting? Segment #3: What are the main clinical areas being highlighted at the SMSNA meeting at AUA2025? Segment #4: What is new or exciting on the horizon in your sub-specialty? Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SMSNA meeting at AUA2025?

AUA2025: Society of Urological Robotic Surgeons Meeting Cohost: Michael D. Stifelman, MD Outline: Segment #1: What is the Society of Urological Robotic Surgeons and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting? Segment #3: What are the main clinical areas being highlighted at the SURS meeting at AUA2025? Segment #4: What is new or exciting on the horizon in your sub-specialty? Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SURS meeting at AUA2025?

AUA2025: Focal Therapy Society Meeting Cohost: Rafael Sanchez-Salas, MD Outline: Segment #1: What is the Focal Therapy Society and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting? Segment #3: What are the main clinical areas being highlighted at the FTS meeting at AUA2025? Segment #4: What is new or exciting on the horizon in your sub-specialty? Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the FTS meeting at AUA2025?

Update Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care Setting Update Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care Setting Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25

AUA2025: Masterclass: Renal Access and Interventions (2025) Cohost: Rob Sweet, MD, FACS, MAMSE and Thomas Chi, MD, MBA Tune in to hear straight from the experts about what you can expect from our NEWLY DESIGNED Full Day Hands-on Skills Trainings at AUA2025! In this episode, Drs. Thomas Chi and Robert Sweet discuss Masterclass: Renal Access and Interventions, an all new interactive training offering skills in percutaneous renal access and image-guided renal interventions. Early Bird deadline for Hands-on Skills trainings has been EXTENDED - ends March 24. Spaces are limited – Register now!

Hereditary Kidney Cancer Syndromes CME Available: https://auau.auanet.org/node/41772 ACKNOWLEDGEMENTS: Support provided by an independent educational grant from:  Merck & Co., Inc.  LEARNING OBJECTIVES: At the conclusion of this activity, participants should be able to: 1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation. 2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members. 3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors. 4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies. 5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.

AUA2025: Fundamentals of Prostate MRI and Transperineal Interventions (2025) Cohost: Arvin K. George, MD and James Wysock, MD, MSc Tune in to hear straight from the experts about what you can expect from our NEWLY DESIGNED Full Day Hands-on Skills Trainings at AUA2025! In this episode, Dr. Arvin K. George and Dr. James Wysock discuss optimizing diagnosis of clinically significant prostate cancer along with a preview of what practicing urologists will gain from attending Fundamentals of Prostate MRI and Transperinal Interventions. Among the skillsets of MRI interpretation, segmentation, fusion-guided transperineal prostate biopsy, and transperineal spacer techniques, attendees also receive access to a library of on-demand virtual didactics straight from the experts! Early Bird deadline for Hands-on Skills trainings ends March 7. Spaces are limited – Register now! https://www.auanet.org/AUA2025/register/hands-on-skills-trainings Outline: Segment #1: The Changing Landscape of Prostate Cancer Diagnostics S

Recognition and Management of Complications Following Gender Affirming Surgery Co-Host: Laura Douglass, MD Outline: Segment #1 Topic: Why is this important for ALL urologists to know? Segment #2 Topic: Introduction to Gender Affirming Surgery (GAS) Segment #3 Topic: Emergency/ED consultations vs. Outpatient/clinic consultations Resources: - Hanley K, Wittenberg H, Gurjala D, Safir MH, Chen EH. Caring for Transgender Patients: Complications of Gender-Affirming Genital Surgeries. Ann Emerg Med. 2021 Sep;78(3):409-415. - Krakowsky Y, Shah G, Nguyen AV, Kavanagh AG, Potter E, Remondini T, Goldsher YW, Millman A. Gender-affirming care in urology: emergency care of the gender-affirming surgical patient-what the primary urologist needs to know. BJU Int. 2024 Feb;133(2):124-131. doi: 10.1111/bju.16249. Epub 2023 Dec 14. PMID: 38060336. - Mann RA, Kasabwala K, Kim N, Pariser JJ. The Management of Complications of Feminizing Gender Affirming Genital Surgery. Urology. 2021 Jun;152:67-73. doi: 10.1016/j.urology.202

AUA Guidelines: Diagnosis and Treatment of Infertility in Men Co-Host: Robert E. Brannigan, MD Outline: Segment #1 Topic: New Table 1 Reviewing “Common Terms” in Semen Analysis and Update to the WHO Semen Analysis Reference Ranges Segment #2 Update to the WHO Semen Analysis Reference Ranges Segment #3 Topic: Y Chromosome Microdeletion Testing Change in Testing Guidance Segment #4 Topic: Pelvic MRI imaging is an option for men with suspected ejaculatory duct obstruction Segment #5 Topic: For couples with recurrent pregnancy loss, clinicians should evaluate the male partner with karyotype (Expert Opinion) and sperm DNA fragmentation Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Brannigan RE, Hermanson L, Kaczmarek J, Kim SK, Kirkby E, Tanrikut C. Updates to male infertility: AUA/ASRM guideline (2024). J Urol. Published online August 15, 2024. doi:10.1097/JU.0000000000004180. https://www.auajournals.org/doi/10.1097/JU.0000000000004180

AUA Guidelines: Diagnosis And Treatment Of Idiopathic Overactive Bladder Co-Host: Anne Pelletier Cameron, MD, FRCSC, URPS Segment #1: Is this an update to the prior Guideline? Segment #2: What is new in the Diagnosis, ntitial Assessment and Initial Management of OAB? Segment#3: What does the Guideline say about Oral Medication? Segment #4: What's new in minimally invasive prodcedures Segment #5: UDS and Cystoscopy Segment #6: What is new and exciting on the horizion for OAB Segment #7: Where to start and the most impactpact research in this area The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. Published online April 23, 2024. doi:10.1097/JU.0000000000003985. https://www.auajournals.org/doi/10.1097/JU.0000000000003985

AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer Guest: Jeffrey M Holzbeierlein, MD Outline: Segment #1: Guideline Statement 9-Patients who have not received cisplatin-based NAC and have pT3-4 and/or N= disease at cystectomy should receive adjuvant cisplatin based chemotherapy or adjuvant immunotherapy. Segment #2: Guideline Statement 11-When performing a cystectomy in males the bladder, prostate cand seminal vesicles should be removed (no change) but in females clinicians should consider removal of adjacent reproductive organs based on individual disease characteristics and need to obtain negative margins. Organ sparing procedures in females should be considered based on disease location and characteristics on an individual basis. Segment #3: Guideline Statement 20-When performing bilateral pelvic lymphadenectomy , clinicians should remove, at a minimum, the external and internal iliac and obturator lymph nodes (standard lymphadenectomy). Segment #4: Future Directions T

Biomarkers and Molecular Imaging for Prostate Cancer CME Available: auau.auanet.org/node/41727 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers. 2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring. 3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

Appropriate Use of Genetic Testing (who, what, when and how?) CME Available: auau.auanet.org/node/41734 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications. 2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration. 3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.

Treatment Intensification in Metastatic HSPC CME Available: https://auau.auanet.org/node/41733 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology.  2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks.  3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.

Sequencing Of Agents CME Available: auau.auanet.org/node/41735 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials. 3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance. 4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.

Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41961 After participating in this CME activity, participants will be able to: 1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions. 2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. 3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC. 4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies. 5. Properly manage adverse events associated with NMIBC treatment. Acknowledgements Support provided by an independent educational grant from: ImmunityBio, Inc. Merck & Co., Inc. UroGen Pharma, Inc.

Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/42040 After participating in this CME activity, participants will be able to: 1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy. 2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes. 3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma. 4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management. 5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes. Acknowledgements Support provided by an independent educational

Complex Cases in Kidney Stone Disease CME Available: https://auau.auanet.org/node/41889 At the conclusion of this activity, participants will be able to: 1. Describe the pathophysiology, genetic basis, and clinical presentation of Primary Hyperoxaluria Type 1. 2. Analyze the unique considerations and challenges in evaluating kidney stones in pediatric patients. 3. Utilize the results of 24-hour urine testing to guide dietary and pharmacologic interventions for stone prevention. 4. Recognize the indications for genetic testing in patients with kidney stones and utilize the results to inform diagnosis and treatment. 5. Employ appropriate patient management and family counseling strategies in consideration of the impact of genetic testing results. 6. Properly refer patients with kidney stone disease to a nephrologist when warranted. ACKNOWLEDGEMENTS: Support provided by an independent educational grant from:  Alnylam Pharmaceuticals, Inc.

Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24

AUA2024: Journal of Urology Lecture: Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color Presenter: Quoc-Dien Trinh, MD, MBA